Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13425477 | 0.88 | LMNA (0.41) | TBXA2RLMNAMEN1KMT2APOLB | |
| SCHEMBL4379489 | 0.85 | LMNA (0.40) | TBXA2RLMNAMEN1KMT2APOLB | |
| SCHEMBL30814318 | 0.83 | LMNA (0.41) | TBXA2RLMNAMEN1KMT2APOLB | |
| SCHEMBL13425952 | 0.82 | LMNA (0.43) | LMNAFAAHMEN1KMT2APOLB | |
| SCHEMBL368032 | 0.81 | CYP1A2 (0.45) | TBXA2RFAAHMEN1KMT2ACYP3A4 | |
| SCHEMBL30814302 | 0.80 | LMNA (0.38) | TBXA2RLMNAMEN1KMT2APOLB | |
| SCHEMBL30814683 | 0.80 | LMNA (0.38) | TBXA2RLMNAMEN1KMT2APOLB | |
| SCHEMBL30814289 | 0.79 | LMNA (0.40) | TBXA2RLMNAMEN1KMT2APOLB | |
| SCHEMBL30728434 | 0.74 | POLB (0.47) | MEN1KMT2APOLBCYP3A4ALDH1A1 | |
| SCHEMBL6581767 | 0.72 | BRD4 (0.43) | FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210009557-A1 | ACYCLIC CXCR4 INHIBITORS AND USES THEREOF | X4 PHARMACEUTICALS, INC. | 2021-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009557-A1 | ACYCLIC CXCR4 INHIBITORS AND USES THEREOF | CXCR4, CXCR3, CXCR1 | TBXA2R 49/4885LMNA 3609/4885FAAH 1745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.